Clinical Trial Update: Decitabine, Cytarabine, GCSF for Refractory AML/MDS [Phase 2]

View source ↗

Summary

Phase 2 trial of decitabine, cytarabine, and GCSF for refractory AML/MDS was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Decitabine (Decitabine)
• G-CSF (granulocyte colony-stimulating factor)

Snippet

Sponsor: Brown University | Conditions: Myelodysplasia, Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2013-07-02